H.C. Wainwright lowered the firm’s price target on Travere Therapeutics to $17 from $20 and keeps a Buy rating on the shares. The firm moderated expectations for the long-term net sales growth trajectory of Filspari to account for the expected expiry of market exclusivity in 2033 and lowered its view of the odds of success for receipt of milestone payments on the divested bile acid products to 25% from 40% previously to “better align with recent biotech milestone achievement statistics,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
- New Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?
- Travere Therapeutics price target raised to $14 from $10 at Citi
- Travere Therapeutics reports Q4 EPS (94c), consensus ($1.22)
- Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results